Cell Line Development Market Set for massive growth | Key Players: GE Healthcare, Sigma-Aldrich, Cytovance Biologics, WuXi AppTec

Global Cell Line Development Market set to exceed USD 7.5 billion by 2024; according to a new research report by Global Market Insights.

Rising incidence of chronic diseases such as cancer, autoimmune disease and inflammatory disorders will drive the global cell line development market during the forecast period. Rapidly growing geriatric population base and unmet need for cancer drugs are the key factors that will fuel the demand for discovery of new drugs, thereby accelerating cell line development industry growth. Increasing adoption of cell line systems for production of vaccines, monoclonal antibodies and lymphokines will boost the demand for cell line cultures. Developments in biotechnology industry coupled with rapidly growing vaccine production across the globe will augment the cell line development market growth.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/429

Advancement in cell line development technologies will serve to be another positive impact rendering factor surging industry growth. Availability of automated screening methods, improved expression systems as well as developments in equipment will further stimulate industry growth. Furthermore, increasing investment in R&D to develop novel technologies and products will upsurge the cell line development market growth. However, stringent regulatory framework for approval of biologics and diagnostic products may hamper the cell line development market growth. Issues related to harvesting human embryonic stem cells that cause destruction of human embryos will further impede the market growth.

Equipment segment is estimated to show lucrative CAGR of 13.1% over the forecast period owing to advancements in cell line development technologies. Rapid development in recombinant protein therapeutic products and improvement in speed and ease of cell line production techniques will fuel the demand for incubators, centrifuges, bioreactors, microscopes and other equipment. Increasing need for safety equipment in cell culture laboratories to eliminate exposure to harmful substances will drive the segmental growth in coming years.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
• GE Healthcare
• Sigma-Aldrich
• Cytovance Biologics
• WuXi AppTec
• Sartorius Stedim Biotech
• Selexis SA
• EuBiologics co.,Ltd
• Paragon Bioservices, Inc.
• Cobra Biologics
• Patheon
• Samsung BioLogics
• GVK BIO
• Cellforcure
• Epistem Ltd.Catalent Applied Drug Delivery Institute
• Bioceros
• Abzena
• Cyagen US Inc.

Recombinant cell lines segment dominated the cell line development market with USD 1.0 billion revenue in 2017 and is projected to witness healthy growth during the analysis period. Increasing demand for recombinant cell lines due to developments in rDNA technology is the major factor that will drive the segmental growth. Growing utilization of recombinant cell lines for production of biosimilars and monoclonal antibodies will upsurge the segmental growth during the forthcoming years.

Drug discovery segment is estimated to witness 12.8% CAGR over the analysis timeframe. The segment growth is highly attributable to development in application of genomics and molecular pharmacology in drug discovery. Growing prevalence of cancer, autoimmune diseases, inflammatory disorders and other chronic diseases will fuel the need for drug discovery. Furthermore, increasing adoption of cell line products for drug screening and lead validation assays will accelerate segmental growth in the coming years.
Cell line development market is rampant with frequent partnerships and strategic collaborations that have contributed toward escalating its revenue graph in recent years. Merely a week earlier, the biopharmaceutical company, Bioasis Technologies Inc., teamed up with Wuxi Biologics to develop and manufacture an investigational biological candidate to treat brain cancer.

As Bioasis is well-known for its technology platform to treat CNS disorders, this strategic initiative will help both the companies overcome the barriers to treating brain-related diseases. In fact, both the companies are planning to develop sophisticated therapies to become experts in cell line and its formulation development. The aforementioned instance validates that the increasing involvement of biological companies to gain expertise in drug development is poised to propel cell line development market size.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/429

Citing yet another instance, a Germany-based biotechnology company and one of the leading providers of therapeutic glycoproteins and antibodies, ProBioGen AG has set a development milestone to commercialize its cancer cell-killing technology. In this regard, it has partnered with a clinical immune-oncology company, Merus, which will use ProBioGen AG’s GlymaxX® technology to treat various types of cancer. The trend of mutually deploying clinical technologies with rival companies to standardize the conventional treating methodology is likely to push cell line development industry share over the years ahead.

U.S. market accounted for USD 1.0 billion in 2017 and is estimated to show similar growth during the analysis period. Increasing prevalence of chronic disease and growing adoption of cell culture techniques are the key factors that will drive the cell line development industry growth. Huge investment in R&D for development of stable cell lines and technological innovations for creating new cell lines will further boost the market growth. Key industry players in the cell line development market have strong foothold in the U.S. that will elevate the regional growth during the forthcoming years.

Global Market Insights Inc. is a global market research and management consulting company catering to leading corporations, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

Global Market Insights, Inc.
4 North Main Street
Selbyville, Delaware 19975 USA
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email:sales@gminsights.com

This release was published on openPR.